amyloid positron emission tomography (amyloid PET)

From Aaushi
Jump to navigation Jump to search

Pathology

Genetics

Indications

Clinical significance

Procedure

Notes

More general terms

More specific terms

References

  1. 1.0 1.1 George J, Solomon HA, Caputo D Amyloid PET Changes Diagnosis, Treatment. Dutch study may boost prospects for insurance, Medicare coverage. MedPage Today. June 11, 2018 https://www.medpagetoday.com/neurology/alzheimersdisease/73412
    de Wilde A, van der Flier WM, Pelkmans W et al Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort: The ABIDE Project. JAMA Neurol. 2018 Jun 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29889941
    Salloway S Improving Evaluation of Patients With Cognitive Impairment With Amyloid Positron Emission Tomography. JAMA Neurol. 2018 Jun 11. PMID: https://www.ncbi.nlm.nih.gov/pubmed/29889928
  2. 2.0 2.1 Boccardi M, Altomare D, Ferrari C et al. Assessment of the incremental diagnostic value of florbetapir F 18 imaging in patients with cognitive impairment: The Incremental Diagnostic Value of Amyloid PET With [18F]- Florbetapir (INDIA-FBP) study. JAMA Neurol 2016 Oct 31; <PubMed> PMID: https://www.ncbi.nlm.nih.gov/pubmed/27802513 <Internet> http://jamanetwork.com/journals/jamaneurology/article-abstract/2578330
  3. 3.0 3.1 Rabinovici GD, Gatsonis C, Apgar C et al Association of Amyloid Positron Emission Tomography With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild Cognitive Impairment or Dementia. JAMA. 2019;321(13):1286-1294 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30938796 https://jamanetwork.com/journals/jama/fullarticle/2729371
    Jack CR Jr, Petersen RC. Amyloid PET and Changes in Clinical Management for Patients With Cognitive Impairment. JAMA. 2019;321(13):1258-1260 PMID: https://www.ncbi.nlm.nih.gov/pubmed/30938781 https://jamanetwork.com/journals/jama/fullarticle/2729351
  4. 4.0 4.1 Altomare D et al. Clinical effect of early vs late amyloid positron emission tomography in memory clinic patients: The AMYPAD-DPMS randomized clinical trial. JAMA Neurol 2023 Jun 1; 80:548. PMID: https://www.ncbi.nlm.nih.gov/pubmed/37155177 PMCID: PMC10167601 Free PMC article https://jamanetwork.com/journals/jamaneurology/fullarticle/2804755
  5. 5.0 5.1 CMS.gov. July 2023 Beta Amyloid Positron Emission Tomography in Dementia and Neurodegenerative Disease. https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=Y&NCAId=308
  6. 6.0 6.1 Jutkowitz E, Shewmaker P, Ford CB et al Association between results of an amyloid PET scan and healthcare utilization in individuals with cognitive impairment. J Am Geriatr Soc. 2024 Mar;72(3):707-717 PMID: https://www.ncbi.nlm.nih.gov/pubmed/38069618 https://agsjournals.onlinelibrary.wiley.com/doi/abs/10.1111/jgs.18696
  7. 7.0 7.1 George J Alzheimer's Amyloid Tied to Circadian Disruption Earlier in Life. Sleep fragmentation may be an Alzheimer's risk factor, data suggest. MedPage Today June 24, 2024 . https://www.medpagetoday.com/neurology/alzheimersdisease/110799
    Nguyen Ho PT, Hoepel SJW, Rodriguez-Ayllon M et al Sleep, 24-Hour Activity Rhythms, and Subsequent Amyloid-beta Pathology. JAMA Neurol. Published online June 24, 2024. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38913396 https://jamanetwork.com/journals/jamaneurology/fullarticle/2820395
  8. 8.0 8.1 Seto M, Hohman TJ, Mormino EC et al. Parental history of memory impairment and beta-amyloid in cognitively unimpaired older adults. JAMA Neurol 2024 Jun 17; [e-pub]. PMID: https://www.ncbi.nlm.nih.gov/pubmed/38884955 https://jamanetwork.com/journals/jamaneurology/fullarticle/2820195